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Cost-effectiveness analysis of advanced stage non-small cell lung cancer 
treatment with cisplatin–vinorelbine and carboplatin–gemcytabine 
combination regimens
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Objectives. The aim of the work is to perform an incremental cost-effectiveness analysis of cisplatin–vinorelbine 
(PN) and carboplatin–gemcytabine (KG) treatment regimens used in advanced stage non-small cell lung cancer 
(NSCLC) treatment.
Material and methods. Medical records of 99 patients with advanced stage NSCLC were collected retrospectively 
at the Oncology Center in Bydgoszcz. The patients were treated with one of the regimens to be analysed between 
2006 and 2011. The analysis was performed from the payer’s perspective. Only direct medical costs were analysed. 
Costs of procedures were obtained from the hospital’s price list of medical services as of June 30th, 2012. Incre-
mental and one-way sensitivity analyses were performed.
Results. The average cost of chemotherapy treatment with the PN treatment regimen is higher than that with the KG 
treatment regimen (25,342.04 PLN and 19,546.80 PLN per patient, respectively). The average survival time of NSCLC 
patients treated with PN and KG treatment regimens was 12.91 and 10.11 months, respectively. The cost of drugs 
constitutes the largest part of the total cost of NSCLC treatment with either treatment regimen. The incremental 
cost-effectiveness ratio (ICER) is 24,836.76 PLN per additional life-year gained.
Conclusion. The analysis showed that the PN treatment regimen is more cost-effective in the treatment of advanced 
NSCLC, when compared to the KG treatment regimen.
Analiza efektywności kosztów leczenia chorych na zaawansowanego niedrobnokomórkowego 
raka płuca chemioterapeutykami zawierającymi cisplatynę–winorelbinę oraz karboplatynę– 
–gemcytabinę
Cel pracy. W pracy porównano koszty i efekty dwóch alternatywnych chemioterapii opartych na schematach cispla-
tyna/winorelbina (PN) oraz karboplatyna/gemcytabina (KG) stosowanych w leczeniu zaawansowanego niedrobno-
komórkowego raka płuca (NDRP). 
Materiał i metody. Koszty oszacowano retrospektywnie na podstawie historii chorób 99 pacjentów leczonych w Cen-
trum Onkologii w Bydgoszczy w latach 2006–2011. Analizę przeprowadzono z perspektywy płatnika. Analizowano 
jedynie bezpośrednie koszty medyczne. Punktem czasowym określenia cen był czerwiec 2012 r. W pracy zastosowano 
analizę efektywności kosztów, obliczono inkrementalny współczynnik efektywności kosztów (IWEK) oraz wykonano 
jednokierunkową analizę wrażliwości. 
Wyniki. Droższą metodą i jednocześnie bardziej skuteczną okazał się schemat PN. Średni koszt leczenia jednego pa-
cjenta schematem PN wyniósł 25 342,04 PLN, a średni czas przeżycia — 12,91 miesiąca. Średni koszt leczenia jednego 
pacjenta wg schematu KG wyniósł 19 546,80 PLN, a średni czas przeżycia — 10,11 miesiąca. Głównym składnikiem 
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kosztów całkowitych w obu schematach jest koszt leków. Wynik przeprowadzonej analizy inkrementalnej przedsta-
wiony w postaci IWEK informuje, że dodatkowy rok życia pacjentów z zaawansowanym NDRP leczonych droższym, 
ale skuteczniejszym schematem (PN), kosztuje 24 836.76 PLN. 
Wnioski. Z przeprowadzonych badań wynika, że stosowanie schematu PN jest strategią bardziej efektywną kosztowo.
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Introduction
Lung cancer is the most common neoplasm in the world. 
Approximately 1.2 million new cases and 1.1 million deaths 
are recorded annually. In the last 60 years, the death rate 
caused by this disease has increased thirty times [1, 2]. In 
Poland, there are over 20 000 registered cases of people 
diagnosed with lung cancer every year, of which 80% are 
diagnosed with non-small cell lung cancer (NSCLC) [3]. The 
majority of patients are diagnosed with advanced stages of 
the disease (stage IIIA, IIIB or IV), and 50–55% of patients are 
diagnosed with metastatic NSCLC. These patients cannot 
be treated with radical surgery [4]. Due to late recognition 
of the disease, the majority of patients receive only symp-
tomatic and palliative treatment. Patients are treated with 
chemotherapy in the advanced stages of the disease to 
relieve cancer complaints. More advanced stages of cancer 
are often the result of poor prognosis and require higher 
costs of treatment. 
Due to increasing costs of the NSCLC treatment, many 
pharmacoeconomic analyses are used to determine the 
most optimal therapy for cancer. Conducting a pharmaco-
economic analysis to select the most health-effective and 
financially efficient method of treatment is therefore crucial 
to effectively manage a limited healthcare budget [5].
Treatment regimens used in NSCLC differ in toxicity, 
health benefits and cost [6, 7], therefore a pharmacoeco-
nomic analysis of alternative regimens has to be performed 
in order to find an optimal therapy, which is the one that is 
the most cost-effective, cures NSCLC most effectively and 
has the least undesirable effects. 
In this work we perform a comparative study of two 
alternative chemotherapy regimens: cisplatin–vinorelbine 
(PN) and carboplatin–gemcytabine (KG), both of which 
are used to treat advanced stage NSCLC in the Oncology 
Center in Bydgoszcz. Both gemcytabine and vinorelbine 
have proved to be effective drugs in the treatment of lung 
cancer. However, there are few sources on the incremental 
analysis of the PN and KG treatment regimens used to treat 
NSCLC [8]. Therefore, the aim of the analysis is to establish 
which of the two regimens is a better method of treatment 
for NSCLC, in terms of its cost and health effects.
Material and methods
99 medical records of patients treated at the Oncology 
Center in Bydgoszcz between 2009 and 2011 were used in the 
analysis. There were three conditions that determined whether 
a patient was to be included in the analysis. He/she was:
 — histopathologically diagnosed with NSCLC,
 — diagnosed with cancer in one of the following stages: 
inoperable IIIA, IIIB, or IV, 
 — treated with a combination of first-line drugs: either 
PN or KG.
50 patients (35 male and 15 female) were treated with 
the PN regimen. The median age of those patients was 
58 years. In the second group of patients there were 49 peo-
ple (27 male and 22 female) who were treated with the KG 
regimen. Their median age was 60 years.
4 patients treated with the PN regimen (8% PN group) 
and 4 patients treated with the KG regimen (8% KG group) 
were diagnosed with inoperable stage III A cancer. 22 pa-
tients treated with the PN regimen (44% PN group) and 
14 patients treated with the KG regimen (29% KG group) 
were diagnosed with stage III B cancer. 24 patients treated 
with the PN regimen (48% PN group) and 31 patients treated 
with the KG regimen (63% KG group) were diagnosed with 
stage IV cancer. 
The cost-effectiveness analysis was performed from 
the payer’s perspective. Individual costs that constitute 
the total cost of NSCLC treatment were determined in 
a contract made between the Oncology Center in Bydgoszcz 
and the NHF. The price of drugs was taken from the drug 
price list of the hospital pharmacy at the time of writing this 
work (June 2012). Therefore, the analysis did not consider 
any discounting of costs. Only the direct medical costs of 
treatment were analyzed. The analysis of the total cost 
was measured from the first chemotherapy cycle, and con-
sisted of calculating the costs of drugs, radiotherapy, hospi-
talization, ambulatory treatment, diagnostic tests, medical 
examinations and treatment of hematologic complications.
The cost-effectiveness of NSCLC treatment was ex-
pressed in terms of incremental cost per additional life-year 
gained. Survival time was measured from the moment a pa-
tient started their chemotherapy treatment. Information 
219
about the death of patients was collected from the National 
Cancer Registry of Poland. The average survival time was 
calculated by analyzing the date of death of 28 patients 
from the PN group and of 20 patients from the KG group. 
A cost-effectiveness analysis was performed by calcu-
lating the incremental cost-effectiveness ratio (ICER). ICER 
is an equation that measures the difference in costs and 
health effects of two or more analyzed treatment regimens.
A one-way sensitivity analysis was performed to deter-
mine how a change in individual costs that constitute the 
greatest share of the total cost of NSCLC treatment would 
affect the result of the incremental analysis.
Results
A detailed list of all the components of the total cost of 
treatment of advanced stage NSCLC in each analyzed group 
is shown in table I.
Drug costs constitute the largest share of the total cost of 
advanced stage NSCLC treatment, regardless of the regimen 
used (34.10% and 37.21% of the total cost of treatment when 
the PN and KG treatment regimen is used, respectively). 
Table II lists all the component costs of the total pharma-
cotherapy cost in each analyzed group, which are the costs 
of: the first and subsequent chemotherapy lines, cytostatic 
drugs preparation, infusion liquids, and drugs used to treat 
undesirable effects.
The doses of regimen PN are cisplatin 75–100 mg/m2 
day 1, vinorelbine 25–30 mg/m2 day 1, 8 of a cycle repeated 
every 21 days. Due to frequently-observed severe side ef-
fects in patients, the cisplatin dose was often reduced. The 
actual average daily cisplatin dose in one chemotherapy 
cycle was 153.38 mg per patient, and that of vinorelbine 
was 90.62 mg per patient. Six patients had poor cisplatin 
tolerance, so it was replaced with a less toxic drug, namely 
carboplatin. Each of those six patients received a carboplatin 
dose of between 230 and 350 mg/m2.
The doses of regimen KG are carboplatin 300– 
–350 mg/m2 or by rule Calverta AUC 6, day 1, gemcytabine 
1000–1250 mg/m2 day 1, 8 of a cycle repeated every 
21 days. The dose was often reduced due to the bad gen-
eral condition of the patients. The carboplatin dose was 
personalized and depended on the individual patient’s 
creatinine clearance. The actual average carboplatin dose 
in one chemotherapy cycle was 500.53 mg per patient, and 
that of gemcytabine was 3045.63 mg per patient. The rest 
period between each cycle of chemotherapy treatment 
with either regimen was 21 days. Patients had an average 
of between 2 and 6 cycles of treatment.
In case of early recurrence or resistance to first-line 
chemotherapy treatment, patients received second and/or 
subsequent lines of chemotherapy. In total, patients from 
the PN group were treated with 37 different chemotherapy 
cycles, and patients from the KG group were treated with 
23 different chemotherapy cycles. The most frequently ad-
ministered drugs in subsequent lines of chemotherapy were 
docetaxel, erlotynib, and pemetrexed. The cost of the second 
and subsequent lines of chemotherapy is high and has 
a significant impact on the total cost of pharmacotherapy, 
regardless of whether a patient was treated with the PN or 
KG combination regimen as the first line of chemotherapy 
(tab. II). Moreover, costs of subsequent lines of chemother-
apy with the PN treatment regimen are higher than those 
of subsequent lines of chemotherapy with the KG treatment 
regimen, due to a more frequent use of the former method 
of treatment. Some of the possible reasons for the more 
frequent use of subsequent lines of chemotherapy with the 
PN, as opposed to with the KG, treatment regimen could 
be a poor response to the former treatment regimen, or 
a good general condition of patients from the PN group, 
which allows them to be treated with more cytostatic drugs. 
Table II shows that the costs of preparation of cyto-
static drugs used in the PN and KG treatment regimens are 
comparable. The cost of pharmacotherapy (which includes 
the costs of drugs used to reduce adverse effects of NSCLC 
treatment, adjunctive drugs, and infusion fluids) constitutes 
a small share of the total cost of drugs in both treatment 
Tabela I. The components of the total cost of advanced stage NSCLC treatment in the PN and KG groups
Source of costs PN KG
Cost (PLN) Average/patient (PLN) % of total cost Cost (PLN) Average/patient (PLN) % of total cost
Drugs 432 072,66 8 641,45 34,10 356 390,01 7 273,27 37,21
Radiotherapy 309 036,00 6 180,72 24,39 195 416,00 3 988,08 20,40
Hospitalization 229 632,00 4 592,64 18,12 183 664,00 3 748,24 19,18
Ambulatory 106 704,00 2 134,08 8,42 100 152,00 2 043,92 10,46
Diagnostics 139 531,20 2 790,62 11,01 85 130,80 1 737,36 8,89
Hematologic complications 7 868,14 157,36 0,62 1 057,68 21,59 0,11
Medical consultations 42 257,80 845,16 3,34 35 982,90 734,34 3,75
TOTAL 1 267 101,80 25 342,04 100,00 957 793,39 19 546,80 100,00
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regimens. Almost six times more infusion fluids were used 
in the PN treatment regimen, mainly due to the necessity 
of body rehydration and prevention of cisplatin-induced 
nephrotoxicity.
Radiotherapy constitutes a significant share of the total 
cost of the advanced stage NSCLC treatment in both of 
the analyzed groups, and was administered in addition 
to chemotherapy treatment, or to treat the side effects of 
an unsuccessful chemotherapy treatment. The total cost of 
radiotherapy in the KG group amounts to 195 416.00 PLN 
(3 988.08 PLN/patient) and is significantly lower than in the PN 
group, which amounts to 309 036.00 PLN (6 180.72 PLN/pa-
tient). The difference in the total radiotherapy cost between 
the two analyzed groups is the result of the higher total 
number of radical radiotherapy cycles which patients from 
the PN group received, and also due to the higher cost of 
this, as opposed to the palliative radiotherapy cycle.
The cost of hospitalization includes “hotel” costs. Pa-
tients were admitted to hospital to receive radiation therapy, 
cytostatic drugs, or due to the patient’s bad general condi-
tion. The total length of hospital stay of patients from the PN 
group was longer than that of patients from the KG group. 
The total length of hospital stay of patients from the 
PN group was 450 days, 272 of which they spent on the 
Chemotherapy Ward, and 178 of which they spent on the 
Radiotherapy or Brachytherapy Ward. The average length 
of hospital stay was 9 days per patient from the PN group. 
The total length of hospital stay of patients from the 
KG group was 365 days, 204 of which they spent on the 
Chemotherapy Ward, and 161 of which they spent on the 
Radiotherapy or Brachytherapy Ward. The average length of 
hospital stay was 7.45 days per patient from the KG group.
The cost of ambulatory treatment constitutes a large 
part of the total cost of the NSCLC treatment (8.42% and 
10.46% of the total cost of treatment with the PN and KG 
treatment regimen, respectively). The cost of diagnostic tests 
also constitutes a large part of the total cost of the NSCLC 
treatment (11.01% and 8.89% of the total cost of treatment 
with the PN and KG treatment regimen, respectively). The 
cost of ambulatory care services included the costs of diag-
nostic procedures and cytostatic drug administration. The 
cost of ambulatory care was similar in both groups.
Diagnostic tests are divided into laboratory and imag-
ing tests. The total cost of diagnostic tests was higher in the 
Table II. The components of the total pharmacotherapy cost in the PN and KG groups
DRUGS Cost (PLN)
PN KG
Total Average/Patient Total Average/patient
CH
EM
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st
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f 1
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 li
ne
Cisplatin
vial 100 mg — 70,20 PLN
17 958,56 359,17 – –
Vinorelbine 
vial 50 mg — 79,38 PLN
25 463,52 509,27 – –
Carboplatin  
vial 450 mg — 85,10 PLN
822,63 16,45 16 902,56 344,95
Gemcytabine
vial 1000 mg — 54,43 PLN
– – 29 673,60 605,58
Cytostatics of subsequent chemotherapy 339 639,05 6 792,78 271 584,80 5 542,55
Compounding of cytostatics 35 880,98 717,62 31 207,77 636,89
PH
AR
M
AC
O
TH
ER
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Y 
O
F 
AD
VE
RS
E
D
RU
G
 R
EA
C
TI
O
N
Analgetic 413,34 8,27 295,68 6,03
Antiemetic 2 305,50 46,11 1 766,99 36,06
Antidiarrheal 4,13 0,08 0,39 0,01
Laxative 42,70 0,85 21,81 0,45
Diastolic 18,75 0,38 - -
Antitussive 159,04 3,18 99,4 2,03
Expectorants 17,12 0,34 - -
Anticoagulants 484,46 9,69 895,11 18,27
Antihaemorrhagics 101,23 2,02 75,70 1,55
Psychotropics 55,56 1,11 71,60 1,46
Other drugs 6 468,96 129,38 3 419,60 69,79
Infusion fluids 2 237,13 44,75 375,00 7,65
TOTAL 432 072,66 8 641,45 356 390,01 7 273,27
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PN group, which was the result of the more frequent use of 
PET and CT type imaging tests, which are by far the most 
expensive types of imaging tests see table III. 
Medical consultations and treatment of hematologi-
cal complications constitute a small portion of the total 
cost of NSCLC treatment. However, it should be noted that 
a significantly higher number of patients treated with the 
PN, as opposed to KG, treatment regimen suffered from leu-
copenia or anemia, which requires the transfusion of a red 
blood cell concentrate. Despite their low cost of treatment, 
hematological complications present a big challenge due to 
their negative effect on patients’ quality of life. 
An incremental cost-effectiveness analysis was per-
formed to compare the cost and health effects of using the 
PN and KG treatment regimens in NSCLC. The results of the 
analysis are shown in table IV. 
The analysis shows that the PN treatment regimen is 
more effective but also more expensive than the KG treat-
ment regimen. Moreover, the difference between the two 
treatment regimens regarding survival rates is small. The 
result of the incremental analysis measured in the incre-
mental cost-effectiveness ratio shows that NSCLC treatment 
with the more expensive but also more effective treatment 
regimen (namely, PN treatment regimen) costs an additional 
2 069.73 PLN per life-month gained, which is an additional 
24 836.76 PLN per life-year gained.
A one-way sensitivity analysis was performed to meas-
ure how a ±10% change in each individual direct cost of 
advanced stage NSCLC treatment would affect the result 
of the incremental analysis (fig. 1).
The results of the analysis show that a change in the 
costs of radiotherapy and drugs would have the greatest im-
pact on the result of the incremental analysis. Furthermore, 
a change in the costs of diagnostic tests and hospitalization 
would have a significant impact on the result of the incremental 
analysis, and a change in the remaining individual direct costs 
that constitute the total cost of treatment would not have 
a significant impact on the result of the incremental analysis.
Discussion
It is estimated that NSCLC diagnostic procedures and 
treatment account for 20% of the total cost of health care 
services that deal with all types of malignant tumors, and 
for approximately 2% of global health care costs [9]. Only 
13–15% of patients live up to five years after being diag-
nosed with NSCLC [10]. 
Table IV. The result of the incremental cost-effectiveness analysis, the average cost of NSCLC treatment per patient, and the average survival rate 
in each of the analyzed groups 
Regimen Life expectancy (months) Cost per life-year gained (PLN) ICER (PLN/month)
PN 12,91 25 342,04 
2 069,73 
KG 10,11 19 546,80 
Table III. The costs of individual diagnostic tests in the analyzed groups
Type of test Average price (PLN) PN KG
Total cost (PLN) Average cost/patient (PLN) Total cost (PLN) Average cost/ patient (PLN)
Laboratory
Hematology 9,43 6 934,00 138,75 7 570,00 154,48
Biochemistry 6,42 11 545,50 230,84 11 924,00 243,38
Immunology 10,00 20,00 0,40 10,00 0,20
Tumor markers 25,00 525,00 10,50 850,00 17,34
Imaging
CT 429,00 63 390,5 1 267,81 28 468,00 580,98
RTG 25,75 1 585,00 31,70 1 250,00 25,50
USG 70,00 1 750,00 35,00 1 960,00 40,01
RM 572,00 9 592,00 191,84 1 056,00 21,55
PET/CT 4 100,00 32 800,00 656,00 16 400,00 334,69
Scintigraphy 308,00 2 833,60 56,67 1 848,00 37,71
Bronchoscopy 220,00 880,00 17,60 1 320,00 26,94
BAC/USG 100,00 400,00 8,00 300,00 6,12
Other 287,66 7 275,60 145,51 12 174,80 248,46
TOTAL 139 531,20 2 790,62 85 130,80 1 737,36
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In highly economically developed countries, expens-
es for health care services are increasing. Any method of 
treatment should be pharmacoeconomically evaluated. 
Conducting a cost-effectiveness analysis, which consists 
of assessing the health effectiveness of a given method of 
treatment in relation to its cost, is crucial in choosing the 
most appropriate pharmacotherapy.
One randomized clinical research which compares effec-
tiveness of the PN and the KG treatment was found among 
the available published results of research studies. It was 
written by Thomas P, Robinet G, Gouva S et al. [11]. They 
describe a case where a total of 100 patients with stage IV 
or stage III NSCLC were randomized. The time to progres-
sion was similar in both groups (140 days in the KG group 
and 148 days in the PN group). Overall, survival rates were 
11.1 months in the KG regimen and 10.1 months in the 
PN regimen. Survival rates of both regimens were found 
within a similar range of effectiveness. The results of the 
cited research differ from the results of our study. Both 
studies indicate a small difference between the PN and the 
KG group regarding survival rates, but our research shows 
that the PN treatment regimen is more effective, whereas 
the other research shows that the KG treatment regimen 
is more effective. The difference might be due to different 
patient selection criteria. Our study also includes patients 
with stage III A cancer, whereas the only eligible patients 
from the clinical research were the ones with stage IIIB 
and IV cancer.
There are many studies found in the available litera-
ture, which compare cost and effectiveness of carboplatin 
and cisplatin in different treatment combinations. One of 
them is a study that compares the cost of treatment with 
a PN regimen to the cost of treatment with a PG (cispla-
tin/gemcytabine) regimen. According to that study, in Po-
land advanced stage NSCLC treatment is less expensive 
with the PN rather than PG treatment regimen, mainly due 
to the high cost of gemcytabine. However, after the patent 
protection for gemcytabine expired, its cost significantly 
decreased. The pharmacoeconomic analysis showed that 
the hospitalization cost is higher when the PN treatment 
regimen is used. Similar results were obtained from other 
research studies [12, 13]. Although carboplatin and cisplatin 
are both platinum derivatives, the results of the pharma-
coeconomic analysis of the PG treatment regimen cannot 
be compared with those obtained from the pharmacoeco-
nomic analysis of the KG treatment regimen performed in 
this work, because carboplatin and cisplatin differ in toxicity 
and anticancer activity, which influences the cost and health 
effectiveness of cancer treatment. 
Slightly different results were obtained from a retro-
spective pharmacoeconomic analysis conducted from the 
perspective of the German Health Care System, in which 
PN, PG and KT (Carboplatin/Paclitaxel) treatment regimens 
were examined. The treatment with the PG regimen proved 
to be the cheapest, and the treatment with the KT regimen, 
the most expensive method of treatment. The incremental 
analysis showed that in Germany, in comparison with the 
PN treatment regimen, the PG treatment regimen is a better 
method of treatment in terms of cost and health effective-
ness [14]. Similar results were obtained from research studies 
conducted in Italy [15]. The cost of treatment with the PG 
regimen was over 10% lower than with the PN regimen. 
Nevertheless, it is difficult to compare the results conduct-
ed in Poland with those carried out in different countries, 
due to the different drug prices in each country, different 
healthcare systems, as well as the difference in the amount 
of money set aside by the Ministry of Health for a more ex-
pensive but also more health-effective method of treatment.
The aim of this work was to compare the cost and health 
effectiveness of chemotherapy treatment with the PN and 
KG treatment regimens. The analysis shows that advanced 
stage NSCLC treatment with the PN treatment regimen is 
more expensive but also has more health benefits (it increas-
es the average survival time by 2.8 months as compared to 
the KG treatment regimen). However, it is important to note 
that the median age of the patients from the KG group was 
slightly higher than that of the patients from the PN group 
(60 and 58 years of age, respectively). Furthermore, there 
Figure 1. The one way sensitivity analysis
1900
Drugs Ambulatory Hematologic
complications
Medical
consultations
Diagnostics 
tests
Radio-
therapy
Hospitalization
ICER +10% –10%
1950
2000
2050
2100
2150
2200
P
L
N
223
were more patients with stage IV cancer in the KG group, 
a fact that might have had an influence on the survival rate 
of patients from the KG group. The KG treatment regimen, 
which is the less toxic (and therefore better tolerated) of the 
two analyzed treatment regimens, is used to treat patients 
at high risk of the undesirable effects of chemotherapy. All 
individual direct costs that constitute the total cost of treat-
ment with the PN treatment regimen are higher than the 
corresponding costs of the total cost of treatment with the 
KG treatment regimen. It must be noted that the total cost 
of advanced stage NSCLC treatment was higher when the 
PN treatment regimen was used, mainly due to the higher 
number of subsequent lines of chemotherapy and radiation 
therapies administered in the PN group. The higher number 
of subsequent lines of chemotherapy and radiotherapies 
administered in this group might indicate a possible bet-
ter general condition of patients from the PN group, or 
a possible worse response to chemotherapy when the PN 
treatment regimen was used. 
According to the one-way sensitivity analysis, a change 
in the costs of radiotherapy and drugs would have the great-
est impact on the result of the incremental analysis. 
In order to determine whether a more health effec-
tive but also more expensive method of treatment is 
cost-effective, it is essential to calculate the break-even 
point for that method of treatment. In year 2012 in Po-
land, the break-even point for any medical procedure was 
99 543.00 PLN per additional life-year gained [16]. As 
the incremental cost-effectiveness analysis showed, the 
total cost of the advanced stage NSCLC treatment with 
the PN treatment regimen is 24 836.76 PLN per additional 
life-year gained, which is a cost that is significantly below 
the break-even point. Therefore, the advanced stage NSCLC 
treatment with this regime is highly cost-effective. 
Conclusions
1. The PN treatment regimen is more effective and more 
expensive than the KG treatment regimen, but the dif-
ference between the two treatment regimens regarding 
survival rates is small and clinically insignificant.
2. The cost of drugs constitutes the largest part of the total 
cost of NSCLC treatment with either treatment regimen.
3. A calculated ICER is 24 836.76 PLN per one year of life 
gained.
4. The advanced stage NSCLC treatment with the PN treat-
ment regimen is highly cost-effective. 
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